Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Douglas A. McIntyre | Oct 12, 2007 at 6:17 AM EDT

Dendreon Has $130 Million More At Its Disposal, If It Wants (DNDN)

Dendreon Corporation (NASDAQ:DNDN) has secured a committed equity financing facility under which it may sell up to $130 million of…

Douglas A. McIntyre | Oct 12, 2007 at 4:01 AM EDT

Amgen: 24/7 & Business Week Compare & Contrast (AMGN, BIIB)

It seems that the thoughts of 24/7 Wall St. aren’t alone in the opinion of Amgen’s (NASDAQ:AMGN) future. In this…

Douglas A. McIntyre | Oct 11, 2007 at 5:57 AM EDT

As Stent Business Falls Apart, Field Gets More Crowded

Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns…

Douglas A. McIntyre | Oct 8, 2007 at 7:46 AM EDT

Invitrogen’s Broader Stem Cell Monitor Kit (IVGN)

Invitrogen Corp. (NASDAQ:IVGN) has announced the launch of a new kit that allows researchers to quickly and reliably monitor the…

Douglas A. McIntyre | Oct 8, 2007 at 7:23 AM EDT

Noven Fails Phase III Lithium Study (NOVN)

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that a Phase 3 clinical study of its developmental once-daily lithium carbonate product did…

Douglas A. McIntyre | Oct 6, 2007 at 3:10 PM EDT

Medtronic (MDT): The Stent Business Gets Worse

Medtronic (MDT) has decided to get into the stent business, making the little mesh tubes that keep arteries open. It…

Douglas A. McIntyre | Oct 5, 2007 at 4:39 AM EDT

Pfizer (PFE) Finally Gets The Message

For Pfizer, it has been a long and painful fall. In early 2004, its shares were just below $39. It…

Douglas A. McIntyre | Oct 4, 2007 at 7:33 AM EDT

Penwest Pharmaceuticals (PPCO) Set For Huge Fall

According to The Associated Press Endo Pharmaceuticals (ENDP). and Penwest Pharmaceuticals (PPCO). said Wednesday the patent on their pain drug…

Douglas A. McIntyre | Oct 4, 2007 at 7:27 AM EDT

Hollis-Eden Pharmaceuticals (HEPH) Up 40%

Hollis-Eden (HEPH) and company in the development of a new class of small molecule compounds based on endogenous steroid hormones,…

Douglas A. McIntyre | Oct 4, 2007 at 5:37 AM EDT

For Boston Scientific (BSX) Stent News Gets More Complex

Stent sales for Boston Scientific (BSX) and Johnson & Johnson (JNJ) have taken a big drop since research began to…

Douglas A. McIntyre | Oct 3, 2007 at 3:17 PM EDT

Trimeris Gives Up On Biojector (TRMS, BJCT)

Trimeris Inc. (NASDAQ:TRMS) is feeling a little after-hour pressure. Roche and Trimeris today provided an update on their combined efforts…

Douglas A. McIntyre | Oct 2, 2007 at 5:34 PM EDT

Metabasis Escapes Biotech Zombiedom (MBRX)

Metabasis Therapeutics (NASDAQ:MBRX) announced after the close today that its MB07133 has been granted orphan medicinal product status for the…

Douglas A. McIntyre | Oct 1, 2007 at 4:58 AM EDT

Pfizer (PFE): Love Thy Neighbor, Until He Sues You

The Nigerian government is suing Pfizer (PFE) claiming that it "deceived patients and caused the death of 11 children in…

Douglas A. McIntyre | Sep 28, 2007 at 1:11 PM EDT

Pfizer (PFE) Not Up On Viagra

A Canadian court ruled that Apotex could not market a generic version of Viagra, Pfizer’s (PFE) massively successful ED drug.…

Douglas A. McIntyre | Sep 26, 2007 at 4:08 PM EDT

SIGA Rocks On Its Small Pox Candidate (SIGA)

SIGA Technologies, Inc. (NASDAQ: SIGA) shares are trading higher after the company announced that its lead smallpox drug, ST-246, has…

1 … 363 364 365 366 367 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Dendreon Has $130 Million More At Its Disposal, If It Wants (DNDN)

Amgen: 24/7 & Business Week Compare & Contrast (AMGN, BIIB)

As Stent Business Falls Apart, Field Gets More Crowded

Invitrogen’s Broader Stem Cell Monitor Kit (IVGN)

Noven Fails Phase III Lithium Study (NOVN)

Medtronic (MDT): The Stent Business Gets Worse

Pfizer (PFE) Finally Gets The Message

Penwest Pharmaceuticals (PPCO) Set For Huge Fall

Hollis-Eden Pharmaceuticals (HEPH) Up 40%

For Boston Scientific (BSX) Stent News Gets More Complex

Trimeris Gives Up On Biojector (TRMS, BJCT)

Metabasis Escapes Biotech Zombiedom (MBRX)

Pfizer (PFE): Love Thy Neighbor, Until He Sues You

Pfizer (PFE) Not Up On Viagra

SIGA Rocks On Its Small Pox Candidate (SIGA)

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Health and Healthcare Articles

All Health and Healthcare Articles

Dendreon Has $130 Million More At Its Disposal, If It Wants (DNDN)

Amgen: 24/7 & Business Week Compare & Contrast (AMGN, BIIB)

As Stent Business Falls Apart, Field Gets More Crowded

Invitrogen’s Broader Stem Cell Monitor Kit (IVGN)

Noven Fails Phase III Lithium Study (NOVN)

Medtronic (MDT): The Stent Business Gets Worse

Pfizer (PFE) Finally Gets The Message

Penwest Pharmaceuticals (PPCO) Set For Huge Fall

Hollis-Eden Pharmaceuticals (HEPH) Up 40%

For Boston Scientific (BSX) Stent News Gets More Complex

Trimeris Gives Up On Biojector (TRMS, BJCT)

Metabasis Escapes Biotech Zombiedom (MBRX)

Pfizer (PFE): Love Thy Neighbor, Until He Sues You

Pfizer (PFE) Not Up On Viagra

SIGA Rocks On Its Small Pox Candidate (SIGA)

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%